Overexpression of HER-2/neu in Patients with Prostatic Adenocarcinoma

被引:5
作者
Zahir, Shokouh Taghipour [1 ]
Tafti, Hamid Fallah [2 ]
Rahmani, Koorosh [2 ]
机构
[1] Shahid Sadoughi Univ Med Sci, Fac Cedicine, Dept Pathol, Yazd, Iran
[2] Shahid Sadoughi Univ Med Sci, Fac Cedicine, Dept Canc Res Ctr, Yazd, Iran
关键词
Prostate; adenocarcinoma; HER-2/neu; prostate specific antigen; GROWTH-FACTOR RECEPTOR; HER2; EXPRESSION; CANCER; PROGRESSION; BREAST; EGFR;
D O I
10.7314/APJCP.2014.15.15.6425
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: Prostatic adenocarcinoma is one of the main causes of cancer death, and its timely diagnosis and preventing its progression dramatically helps improve life indexes. Given the high disease recurrence rate, today, research is more inclined toward exploring causes of recurrence and development, and innovation of modern treatment methods. Several studies have explored over-expression of human epidermal growth factor receptor 2 (HER-2/neu) in prostatic cancer so far, with different results. Thus, it was decided to investigate HER-2/neu overexpression in patients with prostatic adenocarcinoma in Iran. Materials and Methods: A sample size of 40 patients with prostate cancer entered the study, using a cross-sectional, non-randomized sampling method. Parameters studied included patient age at surgery, Gleason score, serum prostatic specific antigen (PSA) before surgery, and positive sample rate after immunohistochemical staining to investigate HER-2/neu overexpression. Results: In terms of HER-2/neu receptor staining rate, of 40 slides, 16 (40%) scored 0, 13 (32.5%) 1+, 7 (17.5%) 2+, and 4 (10%) 3+. In total 27.5% of slides showed HER-2/neu overexpression. In terms of age, an inverse correlation was found (-0.181), but without significance (p=0.263). In terms of serum PSA, the correlation coefficient was 0.449 (p=0.004). With respect to Gleason score, the coefficient was 0.190 (p=0.240). Conclusions: In this study, HER-2/neu overexpression occurred in 27.5% of prostate cancer cases, which is a relatively high figure, compared to similar studies elsewhere. While, we failed to reveal any relationship between HER-2/neu expression status with progression and prognosis of disease, it was demonstrated that the serum PSA level was significantly higher in cases with increased receptor expression.
引用
收藏
页码:6425 / 6428
页数:4
相关论文
共 23 条
[1]   Correlation of AR, EGFR, and HER2 Expression Levels in Prostate Cancer: Immunohistochemical Analysis and Chromogenic In Situ Hybridization [J].
Baek, Kwang Hyun ;
Hong, Min Eui ;
Jung, Yoon Yang ;
Lee, Chung Hun ;
Lee, Tae Jin ;
Park, Eon Sub ;
Kim, Mi Kyung ;
Yoo, Jae Hyung ;
Lee, Soo Whan .
CANCER RESEARCH AND TREATMENT, 2012, 44 (01) :50-56
[2]  
Bai Qiang, 2007, Zhonghua Nan Ke Xue, V13, P414
[3]   Prognostic Implications of Altered Human Epidermal Growth Factor Receptors (HERs) in Gastric Carcinomas: HER2 and HER3 Are Predictors of Poor Outcome [J].
Begnami, Maria D. ;
Fukuda, Emy ;
Fregnani, Jose H. T. G. ;
Nonogaki, Suely ;
Montagnini, Andre L. ;
da Costa, Wilson L., Jr. ;
Soares, Fernando A. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (22) :3030-3036
[4]  
Calvo BF, 2003, CLIN CANCER RES, V9, P1087
[5]   Androgen-independent prostate cancer cells circumvent EGFR inhibition by overexpression of alternative HER receptors and ligands [J].
Carrion-Salip, Dolors ;
Panosa, Clara ;
Menendez, Javier A. ;
Puig, Teresa ;
Oliveras, Gloria ;
Pandiella, Atanasio ;
De Llorens, Rafael ;
Massaguer, Anna .
INTERNATIONAL JOURNAL OF ONCOLOGY, 2012, 41 (03) :1128-1138
[6]   Her-2/neu receptor in prostate cancer development and progression to androgen independence [J].
Di Lorenzo, G ;
Autorino, R ;
De Laurentiis, M ;
Cindolo, L ;
D'Armiento, M ;
Bianco, AR ;
De Placido, S .
TUMORI JOURNAL, 2004, 90 (02) :163-170
[7]   Longterm Followup Assessment of a HER2/neu Peptide (E75) Vaccine for Prevention of Recurrence in High-Risk Prostate Cancer Patients [J].
Gates, Jeremy D. ;
Carmichael, Mark G. ;
Benavides, Linda C. ;
Holmes, Jarrod P. ;
Hueman, Matthew T. ;
Woll, Michael M. ;
Ioannides, Constantine G. ;
Robson, Craig H. ;
McLeod, David G. ;
Ponniah, Sathibalan ;
Peoples, George E. .
JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2009, 208 (02) :193-201
[8]  
Hsing AW, 2000, INT J CANCER, V85, P60, DOI 10.1002/(SICI)1097-0215(20000101)85:1<60::AID-IJC11>3.0.CO
[9]  
2-B
[10]   HER-2/neu is overexpressed infrequently in patients with prostate carcinoma -: Results from the California Cancer Consortium Screening Trial [J].
Lara, PN ;
Meyers, FJ ;
Gray, CR ;
Edwards, RG ;
Gumerlock, PH ;
Kauderer, C ;
Tichauer, G ;
Twardowski, P ;
Doroshow, JH ;
Gandara, DR .
CANCER, 2002, 94 (10) :2584-2589